MCHPP vs NVDA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NVDA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)
As of Nov 16, 2026, Nvidia Corp (NVDA) is the stronger overall head-to-head candidate over Microchip Technology Incorporated Depositary Shares Each Representing a 1/20th Interest in a Share of 7.50% Series A Mandatory Convertible Preferred Stock (MCHPP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MCHPP carries a Unified Composite Score of 57.1/100 (HOLD) at $52.64 (N/M Forward P/E, 21.6% operating margin), whereas NVDA carries 52.4/100 (HOLD) at $156.30 (20.7x Forward P/E, 65.2% operating margin).
- Composite vs. Pillar Nuance: While MCHPP currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. NVDA 52.4/100 HOLD), NVDA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (65.2% vs. 21.6% operating margin) and revenue trajectory (+105.9% vs. +42.2% YoY).
- Technical & Structure Timing Caution: MCHPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.3); meanwhile NVDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MCHPP vs NVDA6-Pillar Scorecard Institutional Category Breakdown (MCHPP 1 – 5 NVDA)
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MCHPP (2) vs NVDA (8)| Institutional Metric | MCHPP | NVDA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | N/A | $4.01T | NVDA | |
| Trailing P/E Ratio | N/M | 21.0x | NVDA | |
| Forward P/E Ratio | N/M | 20.7x | NVDA | |
| Revenue Growth (YoY) | +42.2% | +105.9% | NVDA | |
| Operating Margin (TTM) | 21.6% | 65.2% | NVDA | |
| Net Profit Margin | 15.0% | 63.7% | NVDA | |
| Return on Equity (ROE) | 12.6% | 117.2% | NVDA | |
| 52-Week Range Position | 14% ($47–$88) | 8% ($149–$243) | MCHPP | |
| Beta / 30D Volatility | 2.16β · 65% Vol | 1.77β · 52% Vol | NVDA | |
| Unified Institutional Score | 57.1 / 100 (HOLD) | 52.4 / 100 (HOLD) | MCHPP | |
| Trailing 12M Revenue (USD) | $5.60B | $303.0B | Scale | |
| Gross Profit Margin (TTM) | 62.7% | 74.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 0.21x PEG · 13.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $1.87B EBITDA ($12.20 Book/Sh · 12.6% ROE) | $127.0B ($15.9B Net Debt (0.17x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MCHPP vs NVDA. Trailing 12-month operating profitability (MCHPP 21.6% vs NVDA 65.2%) and valuation multiples (MCHPP N/M vs NVDA 20.7x Forward P/E) are benchmarked directly in Pillar 4 below.